Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. (NYSE: A) is a global company in analytical and clinical laboratory technologies, and its news flow reflects activity across life sciences, diagnostics, and applied markets. Company announcements highlight how Agilent’s instruments, software, services, and expertise are used to help customers bring great science to life, as well as how it manages its financial performance and corporate governance.
On this page, readers can follow Agilent news related to earnings results, product introductions, regulatory-focused solutions, capital allocation, and investor events. Recent releases include quarterly and full-year financial results, with details on revenue, net income, and segment performance for the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. These updates often include management commentary on business conditions and outlook.
Agilent’s news also covers product and technology developments. For example, the company has announced 21 CFR Part 11 compliance software for the xCELLigence RTCA eSight system, designed to support use in GMP-regulated manufacturing and quality control environments by adding secure user authentication, electronic signatures, and audit trails. Another announcement introduced Agilent Altura Ultra Inert HPLC Columns, described as high performance liquid chromatography columns suited for biotherapeutics applications such as peptide GLP-1 and oligonucleotide therapeutic development and quality control.
Investors and analysts can also find updates on capital markets activities, such as cash dividend declarations on Agilent’s common stock, and notices of participation in healthcare and investor conferences. Governance-related news, including leadership transitions and executive appointments, is communicated through press releases and related SEC filings. Bookmarking this page allows users to review Agilent’s ongoing communications about its operations, technologies, financial performance, and corporate developments in one place.
Agilent Technologies Inc. (NYSE: A) has been awarded the 2020 R&D 100 Award for its innovative Vaya Raman raw material identity verification system, recognized in the Analytical/Test category. This handheld spectrometer employs spatially offset Raman spectroscopy (SORS) technology to swiftly identify raw materials while addressing compliance with stringent regulations in the pharmaceutical sector. Launched in March 2020, it enhances testing protocols, allowing for effective identification through various container types, thus improving productivity for users.
Agilent Technologies has expanded Visiopharm’s validated image analysis algorithm to include HercepTest™ mAb pharmDx for Dako Omnis, now CE-IVD marked and available in Europe. This integration allows pathologists to utilize the Visiopharm HER2 APP for more objective assessments of HER2 staining in breast cancer tissue. The algorithm aims to enhance diagnosis accuracy and save time, potentially benefiting patient outcomes by streamlining case management. This advancement represents a significant step towards improving tissue diagnostics efficiency in pathology labs.
MOBILion Systems, Inc., based in Chadds Ford, Pa., announced a successful $35 million Series B funding round led by aMoon, with participation from existing investors including Agilent Technologies (NYSE: A). The funds will support the commercial launch of their Structures for Lossless Ion Manipulation (SLIM) technology aimed at enhancing biomarker discovery and diagnostics. The first product is set for full launch in North America in 2021. MOBILion's SLIM technology is expected to improve the characterization of biologic therapeutics and contribute to COVID-19 research.